8212-Preserved

The overall purpose of the present phase 2 study is to investigate the efficacy and safety of CDR132L in adult participants with heart failure with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH), as an add-on to standard of care (SoC) therapy. The study comprises a 48-week treatment period consisting of a 24-week main phase followed by a 24-week extension phase, and a 12-week follow-up period.